Emerging targets for hematological malignancies

Daniela Cilloni, Francesco Frassoni, Giuseppe Saglio

Research output: Contribution to journalArticlepeer-review


Molecularly targeted therapies have been increasingly incorporated into standard treatment regimens for the majority of hematological malignancies. To increase the efficacy of the next generation of drugs, research efforts have been aimed at identifying molecular defects specific to leukemic cells. A significant therapeutic opportunity is represented by the possibility of selectively eradicating the leukemic stem cell pool. This review focuses on new insights regarding oncogenetic mechanisms in hematological malignancies and related possible druggable targets, including the pathways leading to leukemic stem cell maintenance and the specific approaches used to eliminate them.

Original languageEnglish
Pages (from-to)548-558
Number of pages11
JournalCurrent Opinion in Drug Discovery and Development
Issue number5
Publication statusPublished - Sept 2010


  • Bcl-2
  • hematological malignancy
  • hematopoietic stem cell
  • kinase inhibitor
  • leukemic stem cell
  • transcription factor

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Emerging targets for hematological malignancies'. Together they form a unique fingerprint.

Cite this